Stelfonta is a cancer veterinary medicine used in dogs to treat mast cell tumours that are not suitable for surgery and that have not spread to other parts of the body. These tumours are a type of cancer involving mast cells. These are immune system cells, found in many tissues, that release substances such as histamine. Stelfonta is used for mast cell tumours in the skin, or in mast cell tumours in the tissues just under the skin at or below the elbow or hock. Stelfonta contains the active substance tigilanol tiglate. How is Stelfonta used?
Stelfonta : EPAR - Medicine overview (PDF/120.43 KB)
First published: 11/02/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
QBiotics Netherlands B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
15/01/2020 Stelfonta - EMEA/V/C/005018 -
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
For the treatment of non-resectable, non-metastatic (WHO staging) subcutaneous mast cell tumours located at or distal to the elbow or the hock, and non-resectable, non metastatic cutaneous mast cell tumours in dogs.